Pelican Cancer Foundation

Pelican Cancer Foundation

  • Facebook
  • Instagram
  • Twitter
  • YouTube
DONATE NOW
  • Home
  • About Us
    • About us
    • What we do
      • Bowel cancer
      • Colorectal Liver Metastases
      • Pseudomyxoma peritonei
      • Our Research
      • Our achievements
      • What’s next?
    • Who we are
      • Our board
      • Our team
      • Pelican Patrons
      • Job opportunities
    • Support Us
    • Keep in touch
    • Our annual accounts
  • Workshops
    • Pelican IMPACT
      • IMPACT – Completion & Evaluation
      • Workshops
      • IMPACT – Online resources
      • IMPACT – Partners and Sponsors
    • SPECC
      • SPECC – Completion & Evaluation
      • Workshops
      • SPECC – Online resources
      • SPECC – Partners and Sponsors
    • LOREC
    • TIPTOP
      • Workshops
      • TIPTOP – Online resources
      • Bob’s story (prostate cancer)
      • Andrew’s story (prostate cancer)
      • Alan’s story (prostate cancer)
      • Raymond’s story (prostate cancer)
    • What clinicians say about our courses
    • Faculty
    • Our sponsors
    • Become a sponsor
    • Request a course or topic
    • Give us feedback
    • Previous courses
  • Films
  • Research
    • Research strategy
    • Bowel cancer research
      • POLARS
      • MERCURY 2 (Low Rectal Cancer Study)
      • Deferral of surgery study
      • TATME
      • IMPRESS
      • TRIGGER
      • Papers of interest
      • Timing of surgery
      • AMSOEC
      • MINSTREL
      • Completed research
        • Perineal wound healing registry
        • Beyond TME
        • Validation of the LARS score
        • MARVEL: Evaluation of EMVI positive rectal cancer
        • FLEX
        • TME Physical Simulation Model
        • Total Mesorectal Excision (TME)
        • MERCURY research programme
    • Liver cancer research
      • Completed research
        • EORTC studies
      • SERENADE
      • Papers of interest
    • Peritoneal malignancy research
      • Colorectal Peritoneal Malignancy Database
      • Pseudomyxoma Pathology Atlas
    • Previous Research Areas
      • Prostate Cancer Research
        • Prostate cancer
        • Focal therapy and HIFU research
        • MRI research for prostate cancer
        • Prostate cancer colloquiums
        • FORECAST
        • Trachtomap
        • Papers of interest
      • Bladder cancer research
        • Bladder cancer
        • Papers of interest
    • Peer reviewers
    • Clinical trials
    • Information for researchers
      • Peer review process
      • Research review panel
      • Research Grant Application Guidance Notes
      • Terms and conditions of grants
      • Animals in medical research
      • Research costs
    • Surgical videos
  • For Patients
    • Patient stories
      • Anthony’s story (bowel cancer)
      • Elena’s story (bowel cancer)
      • Terry’s story (liver cancer)
      • Derrick’s story (liver cancer)
      • Alex’s story (colorectal cancer)
      • Cheryll’s story (rectal cancer)
      • Eileen’s story
      • Richard’s story – irrigation
      • Tom’s story – complete response
      • Advanced metastatic bowel cancer
    • What is an MDT?
      • What an MRI reveals
      • Reporting cancer outcomes
    • Bowel cancer
      • Our bowel cancer team
      • About bowel cancer treatment – TME
      • April – Bowel Cancer Awareness Month
      • Low rectal cancer
      • Complete response to chemoradiotherapy in rectal cancer
      • Frequently asked questions about bowel cancer
      • Irrigation for colostomies
      • A patient’s advice
      • Symptom checker
      • Bowel cancer – useful contacts
    • Liver cancer
      • Our liver cancer team
      • About liver cancer treatment
      • Interventional radiology
      • Liver cancer – frequently asked questions
      • Carcinoid and neuroendocrine tumours
      • Liver cancer – want to read more?
    • Pseudomyxoma peritonei
    • Getting a second opinion
    • Clinical trials
      • Current clinical trials
    • Tell us your story
    • Still got questions about cancer?
    • Links
  • Support us
    • Make a donation
      • Make a donation
      • Why donate to Pelican?
      • Donate shares
      • Donate in memory
      • How your donations are spent
    • Fundraising
      • Our fundraisers
      • Fundraising ideas
      • Fundraising challenges
      • Fundraising resources
      • Our events
    • Leaving a Legacy
    • Volunteering Opportunities
    • Could you host a Pelican Talk?
    • Become a Corporate Charity Partner
    • Pelican Film Society
  • Shop
  • Events
  • Contact us

MERCURY research programme

More than 14,500 new patients in the UK are diagnosed each year with cancer of the rectum (the lowest 15cm of the bowel), THAT IS 27% OF ALL NEWLY DIAGNOSED BOWEL CANCERS EACH YEAR. For these patients, incomplete surgical removal of the tumour can result in local tumour recurrence a reduced chance of survival.

Traditionally, post-operative treatment such as chemo-radiotherapy has been given to patients following excision of advanced tumours but tumour recurrence rates in this group of patients remain high, despite advances in optimal surgical techniques (Total Mesorectal Excision surgery, pioneered by Professor Bill Heald in Basingstoke).

The Wessex Cancer Trust and Siemens Medical UK helped us to fund The MERCURY Study – a prospective, European, multidisciplinary project that demonstrated the accuracy and feasibility of MRI (Magnetic Resonance Imaging) as a method of assessing rectal cancer.

This means that using specialised MRI scanning techniques, the features of a rectal tumour can be identified pre-operatively, therefore allowing individualised, optimal treatment to be planned by the multidisciplinary team. Pre-operative therapies can be given to shrink advanced tumours prior to surgery and, early tumours can be identified for which surgery alone is best and pre-operative therapy is not necessary.

The successful results of MERCURY have been presented at medical meetings internationally and published in the BMJ. The MERCURY Study is also cited in the current research evidence for ‘Improving Outcomes in Colorectal Cancer’ from The National Institute of Clinical Excellence.

The MERCURY Study was successful in achieving its aim – to show that pre-operative MRI was equivalent to the corresponding post-operative pathology result and, can therefore be used by the multidisciplinary team for pre-operative treatment planning. It also provided a comprehensive database for the analysis of many other aspects of the management and treatment of patients with rectal cancer.

Patients from MERCURY have been followed up to assess disease recurrence and survival. The results of this follow up have been published in the Journal of Clinical Oncology. Results from this study showed that MRI assessment is superior to other methods in the assessment of overall survival and the local recurrence of the cancer. Another issue that has been highlighted from this database is that patients with low rectal tumours (tumours in the last 6cm of rectum) have a higher risk of incomplete surgical excisions, meaning that the tumour is not completely removed.

The Study Group are now undertaking MERCURY 2 (Low Rectal Cancer Study), using MRI-based, multidisciplinary team management. The primary aim of this study is to reduce the rate of surgery that does not completely remove the tumour in these patients from 30% to less than 10%. This will improve overall survival for patients.

The MERCURY Study Group is a collaboration of specialist colorectal multidisciplinary teams from 12 hospitals in the UK, Sweden, Germany and Norway. Each team consists of surgeons, radiologists, oncologists, pathologists and nurses. Members of the Study Group have attended specialised workshops to ensure high quality, standardised assessment and data reporting for MERCURY research.

These concepts represent a blueprint for the future development of all aspects of management for this – potentially the most curable of all the common cancers.

Pelican Cancer Foundation Follow

Driving innovation and advancing surgery to help patients live well, for longer.

Pelican_Cancer
pelican_cancer Pelican Cancer Foundation @pelican_cancer ·
8 Feb

Excited to be holding our 5th annual workshop for Bowel Cancer Screening Practitoners.

Reply on Twitter 1623258266829455362 Retweet on Twitter 1623258266829455362 1 Like on Twitter 1623258266829455362 5 Twitter 1623258266829455362
pelican_cancer Pelican Cancer Foundation @pelican_cancer ·
28 Nov

👇 Available now - http://pelicancancervideos.org
🎥Complexity and decision making for patients with low rectal cancer

Mr Mark Gudgeon, Professor Heald & Mr Moran
@MGudgeon @ProfessorHeald @Brendan92855812

Reply on Twitter 1597119096096784384 Retweet on Twitter 1597119096096784384 2 Like on Twitter 1597119096096784384 2 Twitter 1597119096096784384
pelican_cancer Pelican Cancer Foundation @pelican_cancer ·
26 Nov

👇 Available now - http://pelicancancervideos.org
🎥Complexity and decision making for patients with low rectal cancer

Mr Mark Gudgeon, Professor Heald & Mr Moran
@MGudgeon @ProfessorHeald @Brendan92855812

Reply on Twitter 1596393313757642752 Retweet on Twitter 1596393313757642752 1 Like on Twitter 1596393313757642752 1 Twitter 1596393313757642752
Load More...

To view our privacy policy - click here.
Registered charity no: 1141911

Copyright © 2023 · Outreach Pro Theme on Genesis Framework · WordPress · Log in